Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7383   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,359 result(s) found. Displaying page 2,177 of 2,218.
    «« First « Previous 2173  2174  2175  2176  2177  2178  2179  2180  2181  Next» Last»»
    EudraCT Number: 2009-017918-69 Sponsor Protocol Number: AB08026 Start Date*: 2011-01-14
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the trea...
    Medical condition: Mélanome non-opérable ou métastasé de stade 3 ou de stade 4, portant une mutation dans le domaine juxta-membranaire de c-kit
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025670 Malignant melanoma stage III LLT
    12.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SK (Prematurely Ended) DE (Prohibited by CA) CZ (Completed) HU (Prematurely Ended) AT (Completed) ES (Prematurely Ended) IT (Prohibited by CA) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000973-40 Sponsor Protocol Number: AB04030 Start Date*: 2008-12-18
    Sponsor Name:AB SCIENCE
    Full Title: A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in...
    Medical condition: gastro-intestinal stromal tumour
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051066 Gastrointestinal stromal tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) DE (Prohibited by CA) AT (Completed) BE (Prematurely Ended) ES (Prematurely Ended) NL (Temporarily Halted) GB (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002430-21 Sponsor Protocol Number: PALOMA Start Date*: 2019-07-17
    Sponsor Name:GWT-TUD GmbH
    Full Title: Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies prior to allogeneic stem cell transplantation in patients with higher risk MDS and oligoblastic AML
    Medical condition: Untreated patients with higher risk MDS and oligoblastic AML eligible and intended for allogeneic HCT within the next 6 months
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003870-21 Sponsor Protocol Number: MG0020 Start Date*: 2023-07-25
    Sponsor Name:UCB Biopharma SRL
    Full Title: An open-label, crossover study to evaluate rozanolixizumab self-administration by study participants with generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-004819-31 Sponsor Protocol Number: 1787/12 Start Date*: 2013-07-08
    Sponsor Name:RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTER
    Full Title: Multicenter open-label RCT to compare colistin alone vs. colistin plus meropenem
    Medical condition: INFECTIONS DUE TO CARBAPENEM RESISTENT GRAM NEGATIVE BACTERIA
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10004047 Bacterial infections NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003450-92 Sponsor Protocol Number: IG1005 Start Date*: 2013-11-23
    Sponsor Name:Instituto Grifols S.A.
    Full Title: EVALUATION OF THE PHARMACOKINETIC PROFILE, CLINICAL EFFICACY AND SAFETY OF THE VON WILLEBRAND FACTOR CONTAINED IN FANHDI® (DOUBLE-INACTIVATED HUMAN ANTI-HEMOPHILIC FACTOR) IN PEDIATRIC PATIENTS WIT...
    Medical condition: Severe von Willebrand disease including types I, II, and III with VWF:RCof <15-20%
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10068986 Von Willebrand's factor activity decreased PT
    14.1 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    14.1 10010331 - Congenital, familial and genetic disorders 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003877-48 Sponsor Protocol Number: TAK-662-1501 Start Date*: 2022-12-21
    Sponsor Name:Takeda
    Full Title: An Open-Label, Single-Dose, Phase 1/2 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Human Protein C (TAK-662) for the Treatment of Congenital Protein C Deficiency in Japanese ...
    Medical condition: Congenital Protein C Deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10051298 Protein C deficiency PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-002007-38 Sponsor Protocol Number: CLTP001A12201E1 Start Date*: 2023-03-01
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: An open-label extension study to investigate efficacy, safety and tolerability of LTP001 in participants with pulmonary arterial hypertension
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005268-71 Sponsor Protocol Number: ML42600 Start Date*: 2021-03-04
    Sponsor Name:Roche Farma S.A.
    Full Title: A PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB TO INVESTIGATE SAFETY AND EFFICACY IN SPANISH PATIENTS WITH UNRESECTABLE OR UNSUITABLE FOR LOCOREGIONAL ...
    Medical condition: Treatment for patients with unresectable HCC who have received no prior systemic treatment and are considered unsuitable for locoregional therapy.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-003361-37 Sponsor Protocol Number: C5041005 Start Date*: 2023-03-06
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2/3, TWO-PART STUDY TO EVALUATE THE EFFICACY AND LONG-TERM SAFETY WITH ORAL ETRASIMOD, 2 MG, ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRI...
    Medical condition: Moderate-to-Severe Atopic Dermatitis with a History of Prior Systemic Treatment Failure
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-002609-93 Sponsor Protocol Number: DRI17224 Start Date*: 2021-09-03
    Sponsor Name:Sanofi aventis recherche et developpement
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, dose-ranging Phase 2 study of rilzabrutinib followed by an open-label extension phase in patients with moderate-to-severe chronic sponta...
    Medical condition: Chronic spontaneous urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) IT (Completed) PL (Completed) GR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-004750-39 Sponsor Protocol Number: LEOSIC Start Date*: 2022-07-08
    Sponsor Name:Herlev Gentofte Hospital - Department of Dermatology and Allergy
    Full Title: The role of Interleukin-1B targeted therapy for patients suffering with allergic contact dermatitis: A randomized controlled trial with Anakinra vs. Placebo.
    Medical condition: Allergic contact dermatitis. Patients with nickel allergy to be specific
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10056265 Allergic contact dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002461-35 Sponsor Protocol Number: PREBOTPilot Start Date*: 2019-12-06
    Sponsor Name:Ruprecht-Karls-University Heidelberg Medical Faculty represented by Universitätsklinikum Heidelberg and its acting Comm
    Full Title: Monocenter, randomized, controlled, open-label, phase-II clinical trial of PREoperative endoscopic injection of BOTulinum toxin in the sphincter of Oddi to reduce postoperative pancreatic fistula a...
    Medical condition: Elective distal pancreatectomy for any underlying disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10013476 Distal pancreatectomy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-004136-26 Sponsor Protocol Number: S67063 Start Date*: 2023-06-28
    Sponsor Name:KU Leuven/UZ Leuven
    Full Title: Pharmacokinetics of edoxaban in geriatric patients with atrial fibrillation
    Medical condition: Stroke prevention in atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10016566 Fibrillation atrial LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002198-20 Sponsor Protocol Number: CLNKLPTXIII07AT17 Start Date*: 2018-11-28
    Sponsor Name:Dr. Franz Köhler Chemie GmbH
    Full Title: A Prospective, randomized, single blind, multicentre Phase III study on organ preservation with Custodiol-N solution compared with Custodiol solution in organ transplantation (kidney, liver and pan...
    Medical condition: patients who will undergo kidney, liver or kidney-pancreatic transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005427-36 Sponsor Protocol Number: NL75654.078.20 Start Date*: 2021-05-26
    Sponsor Name:Erasmus MC Cancer Center [...]
    1. Erasmus MC Cancer Center
    2. Erasmus MC Cancer Center
    Full Title: A multicenter, open label non-randomized phase I/II dose escalation study with extension cohort to determine the safety, tolerability and immune modulating effects of the therapeutic LRPAP1 synthet...
    Medical condition: non small cell lung cancer (NSCLC)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005281-34 Sponsor Protocol Number: NN1535-4591 Start Date*: 2022-01-21
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 52 week study comparing the efficacy and safety of once weekly IcoSema and once weekly insulin icodec, both treatment arms with or without oral anti diabetic drugs, in participants with type 2 di...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NO (Completed) BE (Completed) BG (Completed) PT (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003775-19 Sponsor Protocol Number: EFC16461 Start Date*: 2020-09-23
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: Master protocol of three randomized, double-blind, placebo-controlled, multi center, parallel-group studies of dupilumab in patients with chronic spontaneous urticaria (CSU) who remain symptomatic ...
    Medical condition: Chronic spontaneous urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) GB (GB - no longer in EU/EEA) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000972-38 Sponsor Protocol Number: 212692 Start Date*: 2023-05-17
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase III, observer-blind, randomized, multicenter study to evaluate immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Rotarix Porcine circovirus (PCV)-free liquid a...
    Medical condition: Healthy volunteers (active immunization of infants against gastroenteritis due to rotavirus infection)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003593-17 Sponsor Protocol Number: BNT411-01 Start Date*: 2021-02-18
    Sponsor Name:BioNTech SE
    Full Title: Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in p...
    Medical condition: Chemotherapy-naïve extensive-stage small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2173  2174  2175  2176  2177  2178  2179  2180  2181  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Sep 29 20:35:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA